Alvotech And JAMP Partner On Canadian Biosimilars
Partnership Covers Five Alvotech Biosimilar Candidates
Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.
You may also be interested in...
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.
Teva and Alvotech have announced a major biosimilars alliance covering five products for the US market.
Alvotech has brought in public markets specialist Tanya Zharov as deputy CEO for the firm in Iceland, as it prepares for a public listing.